An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

The Maharashtra Food and Drug Administration (FDA) recently banned the sale, distribution, and use of several fairness creams after dangerous levels of toxic heavy metals, including lead and mercury, were found in the products.

About The Case

Among the products, one named Goree Beauty Cream is of Pakistani origin. The product was reportedly being sold unlawfully in the state.

The FDA labelled the products “Not of Standard Quality” (NSQ), warning consumers against using them as prolonged exposure to heavy metals present in the products can lead to serious health complications associated with skin, kidneys as well as the nervous system.

According to the Maharashtra FDA, the following cosmetic products have been declared unsafe:

1. Goree Beauty Cream
2. Face Fresh Gold
3. Golden Star Beauty Cream

Officials also noted that the products lacked mandatory information like the manufacturer's complete details, batch number, manufacturing date, and expiry date, raising concerns over their authenticity and safety.

Also read: Bryan Johnson Blames Sugary Cereals, Soda and Stress for His Autoimmune Disease; Shares Treatment Plan

What Happens When One Gets Exposed To Lead And Mercury?

If used repeatedly, these toxic substances may be absorbed through the skin, allowing them to accumulate in the body over time.

Excessive exposure to mercury can cause:

• Kidney damage

• Tremors and muscle weakness

• Numbness or tingling sensations

• Memory problems and difficulty concentrating

• Mood changes and irritability

• Skin rashes and discoloration

• Harm to unborn babies during pregnancy

The risk increases with prolonged use, particularly when the products are used on a daily basis over months or years.

Also read: Australia Reports More H5 Bird Flu Cases: Does It Have Pandemic Potential?

On the other hand, lead exposure can cause:

• Damage to the nervous system

• High blood pressure

• Kidney dysfunction

• Fertility problems

• Developmental delays in children

• Pregnancy complications

Even if lead accumulates in the body in small amounts, its repeated use may pose long-term health risks.

Why Are Lead And Mercury Found In Fairness Creams?

Sometimes, mercury is illegally added to skin-lightening products as it suppresses melanin production, temporarily making the skin appear lighter. However, this skin-lightening effect comes at the cost of significant health risks.

Lead may contaminate cosmetic products through poor-quality raw materials or unsafe manufacturing processes. Neither ingredient should be intentionally present in cosmetic creams sold for routine use.

International health agencies have repeatedly warned against skin-lightening creams containing mercury.

In June 2026, the US FDA again cautioned consumers not to use over-the-counter skin-lightening products found to contain mercury or hydroquinone because of the risk of kidney injury, neurological damage, and permanent skin problems.

The Maharashtra FDA's crackdown highlights the hidden dangers of unregulated and illegal fairness creams that contain harmful ingredients.

While these products may promise lighter skin, the presence of toxic heavy metals such as mercury and lead can expose users to potentially irreversible health damage. Consumers are advised to read the labels carefully before purchasing any skincare products that promise complexion-altering effects.

Usually, the most telling symptoms of Alzheimer's disease surface in old age. With no cure and limited ways to detect it early, it is challenging to treat and manage Alzheimer's. However, a recent study says that a new blood test can help in diagnosing Alzheimer's early.

New Blood Test May Predict Alzheimer's Symptoms Early

A new blood test that measures tiny loops of genetic material in the bloodstream may be able to predict when Alzheimer's disease symptoms are likely to appear, offering hope for earlier intervention of the neurodegenerative disease and more effective clinical trials.

A study funded by the U.S. National Institutes of Health (NIH) says that a specific group of blood-based biomarkers known as circular RNAs could help identify people who are on the brink of developing Alzheimer's symptoms, even before memory loss or cognitive decline becomes apparent.

An Improvement On Current Blood Tests

The current blood tests for Alzheimer's have been made after significant progress in recent years, particularly by detecting proteins linked to amyloid plaques, one of the disease's primary characteristics features.

However, these tests may present positive results for many years, even decades, before symptoms like declining memory and thinking appear. It makes it difficult for doctors to predict when the disease will actually begin affecting the patient’s quality of life.

The newly developed blood test could fill that existing gap. Scientists found that elevated levels of a set of 34 circular RNAs in blood were strongly associated with future symptoms of the onset.

According to the study, those with higher circRNA levels were nearly three times more likely to develop Alzheimer's symptoms compared with those with lower levels.

The changes appeared approximately two to four years before symptoms emerged, making them a valuable diagnostic test for predicting disease progression.

Read more: WHO Issues Alert After Fake Cancer Drug Found In Maldives & Mexico; Are Counterfeit Medicines A Global Threat?

How Can This Blood Test Help?

Improve Clinical Testing

The discovery could transform existing Alzheimer's research by helping scientists identify participants who are most likely to develop symptoms during a clinical trial.

Finding out when symptoms are likely to begin would allow researchers to introduce preventive therapies at the stage when they are most likely to be effective and better evaluate whether experimental treatments can delay cognitive decline.

Less Invasive Alternative

The current methods to assess Alzheimer's include PET brain scans, which are expensive and not widely available. Lumbar punctures (spinal taps), an invasive method, is also used.

Compared to the existing methods to screen Alzheimer's, a blood test is easier to perform, less invasive, more affordable and more accessible, especially if validated for widespread clinical use.

Earlier Planning For Patients And Families

If doctors can ascertain the symptoms early, patients and their families can, patients’ families can plan future care and support. They can use the time to make financial and legal decisions while the person is still cognitively healthy. Patients can also adopt lifestyle changes that may help maintain brain health.

Researchers however stressed that the new circRNA test is still in the research stage and requires further validation in larger and more diverse populations before it can be adopted in clinical practice.

The World Health Organization (WHO) has issued a global medical product alert after identifying falsified batches of the cancer medicine DARZALEX (daratumumab). It also issued a warning that the counterfeit products could cause serious health risks to patients and disrupt the treatment process.

WHO Warns Against Fake Cancer Drugs

The WHO issued an alert against the circulation of falsified DARZALEX (daratumumab). The incident came to light in May and June 2026. According to the WHO, the falsified injections were found in the Maldives and Mexico after being supplied by unauthorised distributors.

In at least one reported case, hospitals received fake medication, prompting international concern over gaps in the pharmaceutical supply chain.

About The Cancer Medicine

DARZALEX (daratumumab) is an antibody that is used to treat multiple myeloma, cancer of plasma cells in the bone marrow, as well as amyloid light-chain (AL) amyloidosis, a rare blood disorder.

The drug plays a crucial role in the treatment of various types of cancer. That is why the WHO said that the circulation of its compromised version could cause delayed therapy, treatment failure, and potentially life-threatening consequences.

Read more: Why Sustainable Weight Loss Requires More Than Cutting Calories

WHO Identified The Counterfeit Batch Numbers

WHO said the fake products deliberately misrepresent their identity, composition, or source. The manufacturer, Janssen, confirmed that the batch numbers MYS7381 and STV1K01 are not valid, and any DARZALEX product bearing these batch numbers should be considered falsified and must not be used.

The Maldives Food and Drug Authority also reported visible particulate matter inside vials from one of the counterfeit batches.

The UN health agency has urged national regulatory health bodies, healthcare providers, wholesalers, and distributors to strengthen security across the pharmaceutical supply chains to prevent the infiltration of counterfeits.

It also advised countries to closely monitor unregulated pharmaceutical markets, where counterfeit medicines are more likely to circulate.

Read more: ICMR & IIT Bombay Create Placenta-On-Chip To Study Pregnancy Disorders & Drug Safety

WHO issued precautionary measures to avoid purchasing falsified medications:

• Healthcare professionals should report suspected falsified products, unexpected side effects, or lack of therapeutic effects to their national regulatory authorities and health and disease bodies.

• WHO has advised patients and caregivers to obtain medicines only from licensed pharmacies and authorised healthcare providers.

• Patients must also inspect packaging carefully and seek medical advice if they notice any unusual appearance or suspect their medication may not be genuine.

• The global health organisation stressed that people should not use any product suspected to be falsified and should report it to health authorities immediately.

Falsified Drugs Are A Growing Global Threat

The latest warning adds to a growing list of WHO medical product alerts involving counterfeit cancer medicines.

In recent years, the WHO has issued alerts for various falsified cancer drugs including IMFINZI (durvalumab), IBRANCE (palbociclib) and DEFITELIO (defibrotide), highlighting the growing threat of counterfeit medicines that could disrupt life-saving treatment courses.

The WHO estimates that more than one in ten medical products in underdeveloped and developed countries are either substandard or falsified, making poor-quality medicines one of the world's major public health challenges.